ACME Laboratories Ltd.

ACME Laboratories Ltd.

DDSE:ACMELAB
80.50
BDT
+0.20
(+0.25%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Mizanur Rahman Sinha
Full Time Employees
9,823
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Dhaka Bangladesh
IPO Date
Jun 7, 2016
Business
The ACME Laboratories Ltd. is a Bangladesh-based pharmaceutical company engaged in the research, development, manufacturing, marketing, and distribution of finished pharmaceutical formulations, active pharmaceutical ingredients, herbal and nutraceutical remedies, and veterinary healthcare products. Founded in 1954 and headquartered in Dhaka, Bangladesh, the company operates as an independent publicly listed entity without parent or subsidiary holdings. ACME Laboratories manufactures and markets over 800 pharmaceutical products across diverse therapeutic classes and dosage formats. Its human healthcare product portfolio includes anti-infectives and antibiotics; cardiovascular treatments; antidiabetic medications; gastrointestinal therapies; central nervous system agents; respiratory and pulmonary therapies; analgesics and anti-inflammatory drugs; ophthalmic and dermatological preparations; hormonal and steroid formulations; oncology treatments; and vitamins, minerals, and dietary supplements. The company delivers these products in various dosage forms, including solid dosage tablets and capsules; oral liquids, syrups, and suspensions; sterile blow-fill-seal parenterals and injectable ampoules; dry powder inhalers and rotacaps; topical creams, ointments, and gels; and rectal suppositories. Its veterinary division provides therapeutic boluses, water-soluble powders, oral solutions, and nutritional feed supplements for poultry, dairy, and livestock management. Additionally, the company produces a comprehensive line of traditional Ayurvedic medicines and standardized herbal formulations. ACME Laboratories operates advanced manufacturing facilities in Dhulivita, Dhamrai, designed to conform with international regulatory standards established by the World Health Organization, US FDA, UK MHRA, and Australia TGA, distributing its products domestically across Bangladesh through an integrated logistics network while exporting to international markets across South and Southeast Asia, Africa, the Middle East, Central America, the United Kingdom, and the United States. In recent developments, ACME Laboratories has expanded its therapeutic pipeline with new product introductions, including Emlino (empagliflozin and linagliptin) for glycemic management, Verigat (vericiguat) for cardiovascular therapy, and Trihale 200 Rotacaps for respiratory care. In addition, the company entered into a strategic collaboration with Concept Foundation and CEMAG Care to develop and distribute generic co-packaged mifepristone and misoprostol formulations aimed at expanding global access to quality-assured reproductive healthcare medicines. Operationally, the company has scaled investments in specialized manufacturing infrastructure, establishing dedicated containment facilities for hormone and steroid manufacturing, advanced penicillin and cephalosporin units, and a dedicated active pharmaceutical ingredients synthesis plant situated at the API Industrial Park in Gazaria, Munshiganj, to enhance upstream supply chain resilience and support long-term export growth.